-
Ferroptosis in cardiovascular disease: regulatory mechanisms and therapeutic implications Eur. Heart J. (IF 37.6) Pub Date : 2025-06-04
Yiheng Zhao, Andreas Linkermann, Masafumi Takahashi, Qingguo Li, Xiang ZhouFerroptosis, an iron-dependent form of regulated cell death, has been identified as a key factor in the pathogenesis and progression of various cardiovascular diseases (CVDs). The molecular basis of ferroptosis involves lipid peroxidation, iron dysregulation, and antioxidant pathways. Accumulating evidence suggests that ferroptosis is associated with various CVDs, including atherosclerosis, myocardial
-
Heat extremes and cardiovascular diseases: a scientific statement of the Association of Cardiovascular Nursing & Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, European Heart Rhythm Association of the ESC, the ESC Council on Hypertension, the ESC Council on Stroke, and the ESC Working Group on Cardiovascular Pharmacotherapy Eur. Heart J. (IF 37.6) Pub Date : 2025-06-03
Georgia K Chaseling, Izabella Uchmanowicz, Maria Bäck, Òscar Miró, Maryia Tokmakova, Petter Ljungman, Jari Laukkanen, Rosa Maria Bruno, George Ntaios, Bianca Rocca, Ollie Jay, Lacy M Alexander, W Larry Kenney, Philip MoonsGlobally, hot weather and heatwaves are claiming lives and are predicted to become increasingly deadly under all future climate change scenarios. Rising global temperatures pose a significant risk on cardiovascular health, disproportionately impacting the elderly and people with cardiovascular disease (CVD). However, despite convincing epidemiological data demonstrating this increased cardiovascular
-
Heart failure: assessment of the global economic burden Eur. Heart J. (IF 37.6) Pub Date : 2025-05-30
Mohammad Darvish, Abdul Shakoor, Lida Feyz, Jeroen Schaap, Nicolas M van Mieghem, Rudolf A de Boer, Jasper J Brugts, Robert M A van der BoonBackground and Aims Heart failure (HF) is a major public health issue, imposing substantial costs on healthcare systems and societies. This study aimed to provide a contemporary overview of its global economic impact. Methods A systematic search of four databases was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies reporting direct cost
-
Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial Eur. Heart J. (IF 37.6) Pub Date : 2025-05-30
William A E Parker, Thomas A Nelson, Justin Lee, Heather M Judge, Ramzi A Ajjan, Johan Westerbergh, Agneta Siegbahn, Christina Christersson, John H Alexander, Renato D Lopes, Christopher B Granger, Elaine M Hylek, Lars Wallentin, Robert F StoreyBackground and Aims Oral anticoagulation reduces stroke risk in patients with atrial fibrillation (AF) but increases bleeding. Longer fibrin clot lysis time has been shown to predict adverse cardiovascular outcomes in acute coronary syndromes. This study explored relationships between fibrin clot lysis time at randomization and clinical outcomes in patients with AF enrolled in the Apixaban for Reduction
-
Data sharing statements: impact of journal policies across clinical research disciplines Eur. Heart J. (IF 37.6) Pub Date : 2025-05-30
Daniel Archer, Noah Barks, Mahad Chaudhry, Brody Dennis, Jacob Duncan, Annes Elfar, Taylor Gardner, Eli Paul, Micah Kee, Alicia Ito Ford, Matt VassarBackground and Aims Cardiovascular disease is a leading cause of mortality, with significant investments in research to improve treatment and prevention. Data sharing enhances transparency, reproducibility, and collaboration, yet data sharing statement (DSS) inclusion remains inconsistent. This study evaluates DSS prevalence, content, and influencing factors in high-impact cardiology journals, examines
-
Preventive stenting of vulnerable plaques in diabetic patients: is it worth it? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29
Diana A Gorog -
Rising demand vs limited access: should cardiologists perform mechanical thrombectomy? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29
Peter Lanzer -
Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29
Min Chul Kim, Seung-Jung Park, Duk-Woo Park, Jung-Min Ahn, Do-Yoon Kang, Won-Jang Kim, Chang-Wook Nam, Jin-Ok Jeong, In-Ho Chae, Hiroki Shiomi, Hsien-Li Kao, Joo-Yong Hahn, Sung-Ho Her, Bong-Ki Lee, Tae Hoon Ahn, Kiyuk Chang, Jei Keon Chae, David Smyth, Gary S Mintz, Gregg W Stone, Youngkeun AhnBackground and Aims The efficacy and safety of preventive percutaneous coronary intervention (PCI) for treating vulnerable plaques in diabetic patients remain unclear. Methods The PREVENT (Preventive Coronary Intervention on Stenosis with Functionally Insignificant Vulnerable Plaque) trial was a randomized clinical trial that compared preventive PCI plus optimal medical therapy with optimal medical
-
Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29
K Lance Gould, Nils P Johnson, Amanda E Roby, Richard Kirkeeide, Mary Haynie, Tung Nguyen, Linh Bui, Monica B Patel, Danai Kitkungvan, Patricia Mendoza, Dejian Lai, Ruosha Li, Stefano Sdringola, David McPherson, Jagat NarulaBackground and Aims The randomized CENTURY trial tested the hypothesis that a comprehensive strategy integrating intense lifestyle modification and aggressive medical management to goals with revascularization reserved for severely reduced coronary flow capacity (CFC) by positron emission tomography (PET) would reduce risk factors, subsequent revascularization, death and myocardial infarction (MI)
-
Statins beat device-related in-stent neo-atherosclerosis: pathophysiology reigns supreme. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-27
William Wijns,Shengxian Tu -
Weekly Journal Scan: Extending anticoagulation beyond 6 months after venous thromboembolism in patients with active cancer. Is low-dose apixaban the answer? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-27
Mattia Galli,Carlo Patrono -
Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-26
Mario Berger,Aidan MacNamara,João Pedro Ferreira,Peter Kolkhof,Sebastian Voss,Adam Skubala,Andrea Scalise,Laura Goea,Richard Nkulikiyinka,Bertram Pitt,Joachim Hanno Ix,Peter Rossing,Richard John Mark Coward,Faiez Zannad,Hiddo J L Heerspink -
An update on the Council for Cardiology Practice of the European Society of Cardiology. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-26
Luigina Guasti,Konstantinos Toutouzas,Ruxandra Christodorescu -
Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial Eur. Heart J. (IF 37.6) Pub Date : 2025-05-22
Niki Procopi, Michel Zeitouni, Mathieu Kerneis, Guillaume Cayla, Emile Ferrari, Grégoire Range, Etienne Puymirat, Nicolas Delarche, Paul Guedeney, Farzin Beygui, Laurent Desprets, Jean-Louis Georges, Thomas Bochaton, François Schiele, Grégory Ducrocq, Marie Hauguel-Moreau, Raphaelle Dumaine, Michel S Slama, Laurent Payot, Mohamad El Kasty, Karim Aacha, Abdourahmane Diallo, Xavier Girerd, Eric VicautBackground and Aims This study aims to report the effects of β-blocker interruption on blood pressure (BP) and heart rate (HR) in the AβYSS trial where patients were randomized to interruption or continuation of β-blocker treatment after a myocardial infarction (MI). Methods Changes in HR and BP from baseline to post-randomization are reported using linear mixed repeated model, in the 3698 patients
-
Staring into the AβYSS: how many pills and for how long after myocardial infarction? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-22
John G F Cleland -
Posterior left pericardiotomy in cardiac surgery and outcomes: PALACS-EF trial extended follow-up. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-22
Mario Gaudino,Lamia Harik,Bjorn Redfors,Jordan Leith,Alexander C Gregg,Jessica Kim,Rachel Heise,Lisa Q Rong,Sigrid Sandner,Antonino Di Franco,Charles A Mack,Christopher Lau,Tommaso Sanna,Giovanni J Soletti,Jonathan W Weinsaft,Gianni D Angelini,John H Alexander,Leonard N Girardi -
Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement Eur. Heart J. (IF 37.6) Pub Date : 2025-05-22
Harold Mathijssen, Parag H Bawaskar, Yogita Rochlani, Issac Georgy, Pal Satyajit Singh Athwal, Yugene Guo, Daniel Pollmann, Jeremy Markowitz, Lisa Von Wald, Henri Roukoz, David Perlman, Maneesh Bhargava, Leandro Slipczuk, Annalisa Filtz, Julio Andres Ovalle Ramos, Saurabhi Samant, Sanya Chhikara, Francesco Castagna, Marcel Veltkamp, Fatima Akdim, Annelies L M Bakker, Marco C Post, Chetan ShenoyBackground and Aims Implementing societal recommendations for primary prevention implantable cardioverter-defibrillators (ICDs) in cardiac sarcoidosis requires an accurate diagnosis. However, cardiac sarcoidosis diagnostic schemes are inconsistent and often produce conflicting results. This study aimed to compare the discriminative accuracy of cardiovascular magnetic resonance imaging (CMR) phenotyping
-
New level of evidence grading system for Guidelines, artificial intelligence, and adult congenital heart disease. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21
Filippo Crea -
Checkpoint kinase Wee1 activation drives inflammation and hypertrophy through the protein kinase B/phosphoinositide 3-kinases–nuclear factor κB pathway in cardiomyocytes Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21
Mengyang Wang, Xue Han, Qinyan Wang, Tianxiang Yu, Wu Luo, Shiju Ye, Xiaochen Guo, Zheng Xu, Zhuqi Huang, Julian Min, Ping Huang, Yi Wang, Guang LiangBackground and Aims Hypertensive heart failure has an urgent need for new therapeutic targets. Protein kinases act as key regulators in cellular actions relevant to cardiac pathophysiology. This study identified a protein kinase, Wee1 G2 checkpoint kinase (Wee1), being activated and involved in this disease. Methods RNA-seq-based kinase enrichment analysis was used to identify the involved kinase pathways
-
Weekly Journal Scan: The five-year follow-up of FAME 3 keeps open the never-ending debate about coronary artery bypass grafting vs percutaneous coronary intervention in patients with three-vessel disease. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21
Antonio Maria Leone,Rocco Vergallo -
Catheter ablation in congenital heart diseases: a French nationwide study Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21
Victor Waldmann, Guillaume Duthoit, Jean-Luc Pasquié, Laure Champ-Rigot, Mathieu Albertini, Frédéric Anselme, Stefano Bartoletti, Damien Bonnet, Charlène Bredy, Sok-Sithikun Bun, Gaël Clerici, Antoine Da Costa, Christian De Chillou, Pascal Defaye, Maxime de Guillebon, Clément Davril, Antoine Delinière, Nicolas Derval, Geoffroy Ditac, Kevin Gardey, Caroline Ghanimé, Jean-Baptiste Gourraud, SébastienBackground and Aims Current evidence on catheter ablation for patients with congenital heart disease (CHD) is derived from small, retrospective studies. This study aims to provide insights from a nationwide contemporary registry. Methods This prospective study included all CHD patients referred for catheter ablation from 2020 to July 2024 across 28 French centres. The primary outcome was the rate of
-
Twin pregnancies: impact of infertility treatments and postpartum lifestyle on maternal heart health. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21
Ruby Lin,Cande V Ananth -
Key points for analysing cardiovascular disease after delivery of twin pregnancies. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21
Xin Li,Xue Xiao,Tianjiao Liu -
A 14.6 cm paediatric aortic monster: first LOX mutation shattering size records in childhood thoracic aortic aneurysm and dissection. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21
Nanjun Zhang,Jianfeng Pu,Chuan Wang -
Family history of aortic dissection in fibrillin-1 pathogenic variant. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21
Maria Tchitchinadze,Olivier Milleron,Ludivine Eliahou,Sabrine Jadoui,Nadia Ould Ouali,Nadine Hanna,Pauline Arnaud,Jacques Ropers,Catherine Boileau,Laurent Gouya,Guillaume Jondeau -
Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21
Tomas Baka, Jarrod Moore, Fuzhong Qin, Salva R Yurista, Aifeng Zhang, Huamei He, Jordan M Chambers, Dominique Croteau, Raghuveera K Goel, Hunter Smith, Miranda C Wang, Christopher S Chen, Ion A Hobai, Martina Rombaldova, Ondrej Kuda, Jil C Tardiff, James A Balschi, David R Pimentel, Christine E Seidman, Jonathan G Seidman, Andrew Emili, Wilson S Colucci, Ivan LuptakBackground and Aims Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by left ventricular hypertrophy (LVH), diastolic dysfunction, and impaired metabolic efficiency. This study investigates the therapeutic potential of the sodium–glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin (EMPA) in ameliorating these pathological features in a mouse model carrying the myosin
-
Exercise electrocardiography stress testing in suspected angina and non-obstructive coronary arteries. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21
Robert Sykes,Andrew J Morrow,Bethany Stanley,Daniel Ang,Giles Roditi,David Stobo,David Corcoran,Ninian N Lang,Ahmed Mahrous,Robin Young,David Carrick,Ross McGeoch,Margaret B McEntegart,Alex McConnachie,Novalia P Sidik,Colin Berry -
The Fontan Adult Brompton clinical score and mortality risk Eur. Heart J. (IF 37.6) Pub Date : 2025-05-21
Claudia Montanaro, Alexandra Arvanitaki, William Kerrigan, Zehra Kadani, Rosaria Barracano, Giancarlo Scognamiglio, Aleksander Kempny, Wei Li, Margarita Brida, Ella McDonnell, Hajar Habibi, Konstantinos Dimopoulos, Isma Rafiq, Heng Ee Ling, Harith Alam, Berardo Sarubbi, Gerhard-Paul Diller, Michael A GatzoulisBackground and Aims Adults with congenital heart disease who underwent a Fontan palliation are at increased risk of premature death. This study aimed to identify a risk score based on widely available clinical variables at the first adult visit and facilitate personalized care. Methods A single tertiary centre retrospective study included adults with a Fontan circulation during their first adults with
-
Mortality in male bodybuilding athletes Eur. Heart J. (IF 37.6) Pub Date : 2025-05-20
Marco Vecchiato, Andrea Ermolao, Marco Da Col, Andrea Aghi, Giampaolo Berton, Stefano Palermi, Francesca Battista, Sandro Savino, Jonathan Drezner, Alessandro Zorzi, Josef Niebauer, Daniel NeunhaeusererBackground and Aims Premature deaths of bodybuilders have raised questions about the safety and associated risks of this discipline. The main objective of this study was to analyse mortality risk in a large international population of bodybuilders. Methods Male athletes who performed International Federation of Bodybuilding and Fitness (IFBB) competitions between 2005 and 2020 were identified and classified
-
Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis Eur. Heart J. (IF 37.6) Pub Date : 2025-05-20
Valeria Paradies, Giulia Masiero, Andrea Rubboli, Heleen M M Van Beusekom, Francesco Costa, Piera Capranzano, Sophie Degrauwe, Diana A Gorog, Claudia Moreira Jorge, Gill Louise Buchanan, Mirvat Alasnag, Daniela Trabattoni, Chiara Fraccaro, Dirk Sibbing, Dariusz Dudek, Gemma Vilahur, Alaide Chieffo, Roxana Mehran, Davide Capodanno, Emanuele Barbato, Jolanta M Siller-MatulaThrombotic and bleeding risks differ between sexes, partly in relation to distinct biology and hormonal status, but also due to differences in age, comorbidities, and body size at presentation. Women experience frequent fluctuations of prothrombotic and bleeding status related to menstrual cycle, use of oral contraceptives, hormone replacement therapy, or menopause. Although clinical studies tend to
-
Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation Eur. Heart J. (IF 37.6) Pub Date : 2025-05-20
Kodai Shinzato, Yuya Takahashi, Takanori Yamaguchi, Toyokazu Otsubo, Kana Nakashima, Goro Yoshioka, Kensuke Yokoi, Kotaro Tsuruta, Ryosuke Osako, Shigeki Shichida, Yuki Nishimura, Makoto Edayoshi, Yuki Kawano, Yukako Shintani-Domoto, Kai Miyazaki, Akira Fukui, Atsushi Kawaguchi, Shigehisa Aoki, Seitaro Nomura, Naohiko Takahashi, Kaoru Ito, Koichi NodeBackground and Aims This study aimed to assess the prevalence of cardiac amyloidosis (CA) in patients with non-valvular atrial fibrillation (AF) and to test the hypothesis that early-stage CA can be identified through atrial biopsy. Methods Atrial biopsy was performed on 578 patients during AF ablation, with right ventricular (RV) biopsy conducted in 385 patients. The amyloid type was assessed using
-
Antithrombotic treatment following revascularization for chronic limb-threatening ischaemia: a scientific statement of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy Eur. Heart J. (IF 37.6) Pub Date : 2025-05-20
Oliver Schlager, Marco De Carlo, Lucia Mazzolai, Alessandra Bura-Riviere, Christian Heiss, Jose Rodriguez Palomares, Joao C A Morais, Sabine Steiner, Marianne Brodmann, Victor Aboyans, Raffaele De CaterinaChronic limb-threatening ischaemia (CLTI) is defined as ischaemic rest pain, or non-healing ulceration, requiring endovascular or surgical lower limb revascularization (LLR). Lower limb revascularization in CLTI entails a high risk of major adverse limb events (MALE) and major adverse cardiovascular events (MACE). This scientific statement addresses this risk based on a systematic review. A structured
-
The Polish way to handle the transition from children to adult congenital heart disease. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-20
Lidia Tomkiewicz-Pająk,Paweł Skorek,Jacek Kusa -
Myopericardial complications following COVID-19 disease and vaccination: a clinical consensus statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Eur. Heart J. (IF 37.6) Pub Date : 2025-05-20
Massimo Imazio, Cristina Basso, Antonio Brucato, Karin Klingel, Petr Kuchynka, George Lazaros, Marco Merlo, Gianfranco Sinagra, Yehuda Adler, Chiara Bucciarelli Ducci, Matteo Cameli, Silvia Castelletti, Alida Linda Caforio, Lia Crotti, Lorenzo Dagna, Andrea Frustaci, Allan Klein, Johanna Kuusisto, Angela Lopez Sainz, Renzo Marcolongo, Antonis Pantazis, Angelos G Rigopoulos, Arsen Ristic, Petar SeferovicThe aim of the present clinical consensus statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases is to review the current knowledge on the epidemiology, pathogenesis, diagnosis, therapy, and outcomes of myocardial and pericardial complications of coronavirus disease 2019 (COVID-19) and vaccination in order to improve the awareness and clinical confidence
-
Heart failure: the need for cardiologist-guided follow-up to improve outcomes. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-18
Lars H Lund -
Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort Eur. Heart J. (IF 37.6) Pub Date : 2025-05-18
Guillaume Baudry, Ouarda Pereira, François Roubille, Marc Villaceque, Thibaud Damy, Kévin Duarte, Philippe Tangre, Nicolas GirerdBackground and Aims Outpatient cardiology follow-up is the cornerstone of heart failure (HF) management, requiring adaptation based on patient severity. However, risk stratification using administrative data is scarce, and the association between follow-up and prognosis according to patient risk has yet to be described at a population level. This study aimed to describe prognosis and management across
-
Coronary artery bypass grafting with or without preoperative physiological stenosis assessment: a SWEDEHEART study Eur. Heart J. (IF 37.6) Pub Date : 2025-05-16
Emma C Hansson, Elmir Omerovic, Dimitrios Venetsanos, Joakim Alfredsson, Andreas Martinsson, Björn Redfors, Amar Taha, Susanne J Nielsen, Anders JeppssonBackground and Aims Physiological flow assessment of coronary stenoses, such as fractional flow reserve, are routinely used to guide percutaneous coronary intervention, but it has not been equally recognized to guide coronary artery bypass grafting (CABG). Mid-term outcomes in CABG patients with and without preoperative flow assessment were compared. Methods All patients with first-time isolated CABG
-
Pre-arrest electrocardiogram changes due to vasospastic angina. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-16
Tomohiro Fujisaki,Toshihiro Nakamura,Kengo Kusano -
New treatments and biomarkers in heart failure, hypertrophic cardiomyopathy, and familial hypercholesterolaemia. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-14
Filippo Crea -
Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality Eur. Heart J. (IF 37.6) Pub Date : 2025-05-14
Yuxia Wei, Tomas Andersson, Tiinamaija Tuomi, Thomas Nyström, Sofia CarlssonBackground and Aims The prognosis of adult-onset type 1 diabetes (T1D) and prognostic factors are sparsely investigated. This study assessed mortality, major adverse cardiovascular events (MACE), and prognostic factors in adult-onset T1D, particularly focusing on those diagnosed at age ≥40. Methods Participants were people diagnosed with adult-onset T1D (n = 10 184) or type 2 diabetes (T2D, n = 375
-
Cardiomyopathy caused by mitochondrial DNA 4300A > G variant. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-13
Anshuman Sengupta,Mohammed Majid Akhtar,Abid Mohammed Akhtar,Massimiliano Lorenzini,Thomas Slater,Petros Syrris,Konstantinos Savvatis,Athanasios Bakalakos,Perry Mark Elliott -
Acquired von Willebrand syndrome caused by paravalvular prosthetic mitral regurgitation. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-13
Eri Ishikawa,Shigetaka Kageyama -
Acute coronary syndromes: mechanisms, challenges, and new opportunities Eur. Heart J. (IF 37.6) Pub Date : 2025-05-13
Simon Kraler, Christian Mueller, Peter Libby, Deepak L BhattDespite advances in research and patient management, atherosclerosis and its dreaded acute and chronic sequelae continue to account for one out of three deaths globally. The vast majority of acute coronary syndromes (ACS) arise from either plaque rupture or erosion, but other mechanisms, including calcific nodules, embolism, spontaneous coronary artery dissection, coronary spasm, and microvascular
-
Age-specific troponin thresholds: considerations for the fifth universal definition of myocardial infarction. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-09
Mark Coyle,John W McEvoy -
From small Dutch cohort studies to large-scale nationwide data: impact of COVID-19 on the risk of pulmonary embolism. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-09
Florian Langer -
Bicuspid aortic valve disease: advancements and challenges of transcatheter aortic valve implantation. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-09
Marco Barbanti,Giuliano Costa,Stephan Windecker,Francesco Maisano,Giulia Laterra,Jonathon Leipsic,Philipp Blanke,Vinayak N Bapat,Martin B Leon,John G WebbTranscatheter aortic valve implantation (TAVI) has revolutionized the treatment of patients with severe aortic stenosis (AS). Initially developed for patients with tricuspid aortic valve (TAV) anatomy, the procedural success and expanding indications of TAVI have spurred interest in its application to more complex aortic valve anatomies, such as the bicuspid aortic valve (BAV). The growing interest
-
Spatial transcriptional landscape of human heart failure Eur. Heart J. (IF 37.6) Pub Date : 2025-05-08
Sang Eun Lee, Jeong Ho Joo, Hee Sang Hwang, Shang-Fu Chen, Douglas Evans, Kyoung Yul Lee, Kyung-Hee Kim, Junho Hyun, Min-Seok Kim, Sung-Ho Jung, Jae-Joong Kim, Jeong Seok Lee, Ali TorkamaniBackground and Aims Heart failure (HF) remains a significant clinical challenge due to its diverse aetiologies and complex pathophysiology. The molecular alterations specific to distinct cell types and histological patterns during HF progression are still poorly characterized. This study aimed to explore cell-type- and histology-specific gene expression profiles in cardiomyopathies. Methods Ninety
-
Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database Eur. Heart J. (IF 37.6) Pub Date : 2025-05-07
Diane E MacDougall, Anne Tybjærg-Hansen, Joshua W Knowles, Theresa P Stern, Bonnie K Hartsuff, Mary P McGowan, Seth J Baum, Katherine A Wilemon, Børge G NordestgaardBackground and Aims Higher levels of lipoprotein(a) drive increasing risk of atherosclerotic cardiovascular disease (ASCVD) in otherwise healthy individuals regardless of sex and race/ethnicity. This study aimed to evaluate whether this is also true for recurrent ASCVD, and whether LDL cholesterol-lowering therapy possibly mitigates such a relationship. Methods In US medical claims between 2012 and
-
Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-07
Stefano Romeo,Antonio Vidal-Puig,Mansoor Husain,Rexford Ahima,Marcello Arca,Deepak L Bhatt,Anna Mae Diehl,Luigi Fontana,Roger Foo,Gema Frühbeck,Julia Kozlitina,Eva Lonn,Francois Pattou,Jogchum Plat,Susan E Quaggin,Paul M Ridker,Mikael Rydén,Nicola Segata,Katherine R Tuttle,Subodh Verma,Jeanine Roeters van Lennep,Marianne Benn,Christoph J Binder,Oveis Jamialahmadi,Rosie Perkins,Alberico L Catapano,LaleObesity rates have surged since 1990 worldwide. This rise is paralleled by increases in pathological processes affecting organs such as the heart, liver, and kidneys, here termed systemic metabolic disorders (SMDs). For clinical management of SMD, the European Atherosclerosis Society proposes a pathophysiology-based system comprising three stages: Stage 1, where metabolic abnormalities such as dysfunctional
-
Illicit stimulants and ventricular arrhythmias: a longitudinal cohort study. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-07
Jean Jacques Noubiap,Thomas A Dewland,Gabrielle C Montenegro,Hannah H Oo,Zian H Tseng,Gregory M MarcusBACKGROUND AND AIMS Ventricular tachycardia and ventricular fibrillation underlie many sudden cardiac deaths, but common lifestyle factors that predict their occurrence are poorly understood. This study aimed to assess the association between methamphetamine and cocaine, the most used illicit stimulants, and ventricular arrhythmias (VA) and mortality. METHODS Healthcare databases were used to identify
-
Key topics: sex-related differences in vascular surgery; atrial fibrillation and cognitive performance; and gene therapy of ventricular arrhythmias. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-07
Filippo Crea -
Cutting-edge innovation and global collaboration: the 2024 Great Wall International Congress of Cardiology in China. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-06
Feng Cao,Yabin Wang,Changsheng Ma -
European Research Council-funded grant: tight junctions and heart regeneration. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-06
Christopher Yu Tai Yen,Sofia Kagioglou,Elif Eroglu -
Targeting mitochondrial fission for the treatment of myocardial infarction. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-06
Christopher G R Perry,Gary Sweeney -
Setting the standard: Massimo Piepoli takes on lead editorial role. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-06
Judith Ozkan -
Leducq-funded programme: immune targets for the treatment of atrial fibrillation. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-06
Sebastian Clauss,Matthias Nahrendorf,Stefan Kääb -
Weekly Journal Scan: does dapagliflozin expand the therapeutic options after transcatheter aortic valve implantation? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-06
Daniela Pedicino,Giovanna Liuzzo -
CMR: a gatekeeper before ICA in a stable non ST-elevation myocardial infarction patient with severely impaired LV function. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-06
Georgios Oikonomou,Kevin Cheng,Raad H Mohiaddin -
Fellow of the European Society of Cardiology: recognizing excellence in cardiology. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-06
Dan Atar,Marco Roffi -
Mind the gaps: blood pressure variability and its impact on health. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-06
Sofie Brouwers